{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,4,23]],"date-time":"2023-04-23T16:36:35Z","timestamp":1682267795817},"reference-count":25,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2013,6,1]],"date-time":"2013-06-01T00:00:00Z","timestamp":1370044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,7]],"date-time":"2020-01-07T00:00:00Z","timestamp":1578355200000},"content-version":"vor","delay-in-days":2411,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1093\/annonc\/mdt173","type":"journal-article","created":{"date-parts":[[2013,5,21]],"date-time":"2013-05-21T15:24:18Z","timestamp":1369149858000},"page":"1424-1426","source":"Crossref","is-referenced-by-count":12,"title":["Prevention of chemotherapy-induced peripheral neuropathy: a matter of personalized treatment?"],"prefix":"10.1016","volume":"24","author":[{"given":"T.J.","family":"Postma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.C.","family":"Reijneveld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.J.","family":"Heimans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdt173_bb0010","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s11912-005-0067-0","article-title":"Chemotherapy-induced peripheral neuropathy: an increasing concern for oncologists","volume":"7","author":"Markman","year":"2005","journal-title":"Curr Oncol Rep"},{"issue":"1","key":"10.1093\/annonc\/mdt173_bb0015","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.critrevonc.2011.04.012","article-title":"Chemotherapy-induced peripheral neuropathy (CIPN): an update","volume":"82","author":"Argyriou","year":"2012","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1093\/annonc\/mdt173_bb0020","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/BF01240117","article-title":"Clinical response versus clinical benefit in oncology: not necessarily equivalent terms","volume":"123","author":"Markman","year":"1997","journal-title":"J Cancer Res Clin Oncol"},{"issue":"15","key":"10.1093\/annonc\/mdt173_bb0025","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.2165\/00003495-200363150-00003","article-title":"Neurotoxic complications of chemotherapy in patients with cancer: clinical signs and optimal management","volume":"63","author":"Verstappen","year":"2003","journal-title":"Drugs"},{"issue":"Suppl 4","key":"10.1093\/annonc\/mdt173_bb0030","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1093\/neuonc\/nos203","article-title":"Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention","volume":"14","author":"Grisold","year":"2012","journal-title":"Neuro Oncol"},{"issue":"7","key":"10.1093\/annonc\/mdt173_bb0035","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1200\/JCO.2007.15.3767","article-title":"Oxaliplatin-related neurotoxicity: interest of calcium-magnesium infusion and no impact on its efficacy","volume":"26","author":"Gamelin","year":"2008","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1093\/annonc\/mdt173_bb0040","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1200\/JCO.2010.31.5911","article-title":"Intravenous calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: NCCTG N04C7","volume":"29","author":"Grothey","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdt173_bb0045","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/PL00007853","article-title":"Chemotherapy-induced peripheral neuropathy","volume":"249","author":"Quasthoff","year":"2002","journal-title":"J Neurol"},{"issue":"1","key":"10.1093\/annonc\/mdt173_bb0050","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ejca.2005.06.030","article-title":"Peripheral neuropathy: a persisting challenge in paclitaxel-based regimes","volume":"42","author":"Mielke","year":"2006","journal-title":"Eur J Cancer"},{"issue":"6","key":"10.1093\/annonc\/mdt173_bb0055","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1097\/CCO.0b013e3282a08f8c","article-title":"Individualized chemotherapy with paclitaxel","volume":"19","author":"Mielke","year":"2007","journal-title":"Curr Opin Oncol"},{"key":"10.1093\/annonc\/mdt173_bb0060","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/S1470-2045(11)70131-0","article-title":"Chemotherapy-induced peripheral neurotoxicity in the era of pharmacogenomics","volume":"12","author":"Cavaletti","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdt173_bb0065","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1093\/annonc\/mdt018","article-title":"CYP2C8*3 increases risk of neuropathy in breast cancer patients treated with paclitaxel","volume":"24","author":"Hertz","year":"2013","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1093\/annonc\/mdt173_bb0070","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/j.1742-7843.2008.00351.x","article-title":"Pharmacogenetic studies of paclitaxel in the treatment of ovarian cancer","volume":"104","author":"Gr\u00e9en","year":"2009","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"2","key":"10.1093\/annonc\/mdt173_bb0075","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/tpj.2010.13","article-title":"Polymorphisms in cytochromes P450 2C8 and 3A5 are associated with paclitaxel neurotoxicity","volume":"112","author":"Leskel\u00e4","year":"2011","journal-title":"Pharmacogenomics"},{"issue":"1","key":"10.1093\/annonc\/mdt173_bb0080","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s10549-012-2054-0","article-title":"CYP2C8*3 predicts benefit\/risk profile in breast cancer patients receiving neoadjuvant paclitaxel","volume":"134","author":"Hertz","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"10.1093\/annonc\/mdt173_bb0085","doi-asserted-by":"crossref","first-page":"4528","DOI":"10.1200\/JCO.2006.10.4752","article-title":"Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish randomized trial in ovarian cancer","volume":"25","author":"Marsh","year":"2007","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1093\/annonc\/mdt173_bb0090","doi-asserted-by":"crossref","first-page":"3455","DOI":"10.1158\/1078-0432.CCR-10-2209","article-title":"Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer","volume":"17","author":"Deenen","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1093\/annonc\/mdt173_bb0095","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1212\/WNL.53.8.1660","article-title":"Total neuropathy score: validation and reliability study","volume":"53","author":"Cornblath","year":"1999","journal-title":"Neurology"},{"issue":"3","key":"10.1093\/annonc\/mdt173_bb0100","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/j.1529-8027.2011.00351.x","article-title":"Chemotherapy-induced peripheral neurotoxicity can be misdiagnosed by the National Cancer Institute Common Toxicity scale","volume":"16","author":"Frigeni","year":"2011","journal-title":"J Peripher Nerv Syst"},{"key":"10.1093\/annonc\/mdt173_bb0105","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1023\/A:1008344507482","article-title":"Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy","volume":"9","author":"Postma","year":"1998","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdt173_bb0110","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/j.1529-8027.2010.00292.x","article-title":"Measures of chemotherapy-induced peripheral neuropathy: a systematic review of psychometric properties","volume":"15","author":"Griffith","year":"2010","journal-title":"J Peripher Nerv Syst"},{"issue":"6","key":"10.1093\/annonc\/mdt173_bb0115","first-page":"741","article-title":"Psychometric evaluation of the Functional Assessment of Cancer Therapy\/Gynecologic Oncology Group-Neurotoxicity (Fact\/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy","volume":"13","author":"Calhoun","year":"2003","journal-title":"Int J Gynecol Cancer"},{"issue":"8","key":"10.1093\/annonc\/mdt173_bb0120","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.ejca.2005.02.012","article-title":"The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20","volume":"41","author":"Postma","year":"2005","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdt173_bb0125","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1529-8027.2009.00214.x","article-title":"CI-PERINOMS: chemotherapy-induced peripheral neuropathy outcome measures study","volume":"14","author":"The CI-PERINOMS study group","year":"2009","journal-title":"J Peripher Nerv Syst"},{"issue":"2","key":"10.1093\/annonc\/mdt173_bb0130","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1093\/annonc\/mds329","article-title":"The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings","volume":"24","author":"Cavaletti","year":"2013","journal-title":"Ann Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419373296?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419373296?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/24\/6\/1424\/438069\/mdt173.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T09:06:27Z","timestamp":1624698387000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419373296"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["S0923753419373296"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdt173","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2013,6]]}}}